Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.48 |
| ▸ | NR1I3 | Q14994 | 14/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22633809 | 0.82 | NPC1 (0.57) | RPS6KA3CHEK2NR1I3TEKKDR | |
| SCHEMBL4771935 | 0.82 | TEK (0.59) | RPS6KA3CHEK2NR1I3TEKKDR | |
| SCHEMBL4771368 | 0.82 | NR1I3 (0.52) | RPS6KA3CHEK2NR1I3NR1I2THRB | |
| SCHEMBL13551703 | 0.80 | TEK (0.43) | RPS6KA3CHEK2NR1I3NR1I2THRB | |
| SCHEMBL13551611 | 0.80 | TEK (0.47) | RPS6KA3CHEK2NR1I3NR1I2THRB | |
| SCHEMBL22633832 | 0.79 | NR1I3 (0.54) | RPS6KA3CHEK2NR1I3TEKKDR | |
| SCHEMBL22633918 | 0.79 | NR1I3 (0.54) | RPS6KA3CHEK2NR1I3NR1I2THRB | |
| SCHEMBL22633836 | 0.79 | NR1I3 (0.54) | RPS6KA3CHEK2NR1I3TEKKDR | |
| SCHEMBL13387977 | 0.79 | NPC1 (0.60) | RPS6KA3CHEK2NR1I3TEKKDR | |
| SCHEMBL13551700 | 0.78 | TEK (0.42) | RPS6KA3CHEK2NR1I3NR1I2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | CYP2A6, CYP2B6, CYP4A11 | RPS6KA3 3707/4885CHEK2 1146/4885NR1I3 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.